AVIR — Atea Pharmaceuticals, Inc.

Summary of Atea Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Atea reported cash, cash equivalents, and marketable securities of $301.8 million as of December 31, 2025, providing a strong financial foundation to support ongoing projects.
• R&D Expenses: Increased in 2025 primarily due to external spending on the HCV Phase III clinical development.
• G&A Expenses: Decreased year-over-year, mainly due to lower stock-based compensation, though partially offset by increased professional fees.
• Shareholder Returns: Atea returned $25 million to shareholders through a share repurchase program in 2025.

2. Strategic Updates and Business Highlights

• HCV Program: Progress in the global Phase III trials for bemnifosbuvir and ruzasvir, with C-BEYOND trial enrollment completed (880 patients) and C-FORWARD expected to complete enrollment by mid-2026. Top-line results are anticipated midyear for C-BEYOND and by year-end for C-FORWARD.
• HEV Program: Atea has expanded its pipeline to include AT-587 for chronic hepatitis E, with plans to initiate a first-in-human study midyear 2026.
• Market Need: Highlighted the increasing incidence of HCV infections in the U.S., with only 85,000 out of 160,000 new cases treated annually, emphasizing the need for new therapies.

3. Forward Guidance and Outlook

• Cash Runway: Projected to extend through 2027, allowing for continued investment in both HCV and HEV programs.
• Commercial Launch: Preparations are underway for the commercial launch of the HCV regimen, with a focus on a specialty sales force of approximately 75 personnel.
• Profitability: Expected to achieve profitability shortly after the launch of the HCV product.

4. Bad News, Challenges, or Points of Concern

• Market Competition: The HCV market is competitive, with existing therapies facing pricing pressures. Atea must navigate a landscape where legacy regimens like Epclusa are well-established.
• Regulatory Risks: The success of the HCV program hinges on upcoming trial results and subsequent regulatory approvals, which carry inherent risks.
• Enrollment Challenges: While cirrhotic enrollment for C-BEYOND was successful, maintaining momentum in C-FORWARD is crucial, and any delays could impact timelines.

5. Notable Q&A Insights

• Enrollment Confidence: Management expressed confidence in achieving enrollment targets for C-FORWARD based on successful enrollment in C-BEYOND.
• Commercial Landscape: The company is actively engaging with payers and prescribers, indicating a favorable response to the BEM-RZR regimen's profile, which may aid in formulary inclusion.
• Physician Adoption: Market research suggests that physicians are likely to prescribe the new regimen to about 50% of their patients, contingent on clinical data supporting its efficacy and safety.
• Licensing Agreement: Atea has in-licensed ruzasvir from Merck, with milestone payments tied to regulatory submissions and approvals, indicating ongoing financial commitments.

Overall, Atea Pharmaceuticals is positioned for significant developments in 2026, with a focus on advancing its HCV and HEV programs while navigating a competitive landscape and preparing for commercial launch.